uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course
Regenxbio Inc RGNX
$9.69
▼ -4.25%
($-0.43)
🔥 High Short Interest
📅 Earnings This Week
Open
$10.25
Prev Close
$10.12
Day Range
$9.64 – $10.38
52W Range
$5.46 – $16.19
Market Cap
$632.86M
Beta
0.91
EPS (TTM)
$-5.59
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-09-17 |
| Shares Out. | 63,290,000 |
| Website | regenxbio.com/ ↗ |
| Phone | 12405528181 |
| Employees | 371 |
| Revenue | $6.4M |
| Gross Profit | -$4.7M |
| Net Income | -$90.1M |
| Free Cash Flow | -$236.4M |
| Total Assets | $341.9M |
| Total Liabilities | $320.8M |
| Equity | $21.1M |
About Regenxbio Inc
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Regenxbio Inc is a publicly traded company under the ticker symbol RGNX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)